BRAFV600E 형질전환 마우스를 이용한 갑상선유두암 모델의 확립
Model Development of Papillary Thyroid Carcinoma by BRAFV600E Transgenic Mice
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Objectives: The BRAF^(V600E) mutation has been regarded as the leading cause of papillary thyroid cancer (PTC). However, the multi-step carcinogenic process induced by BRAF^(V600E) has been remained to be elucidated in thyroid gland. In this study, to investigate staged development of papillary thyroid carcinoma, we observed the histo-pathological findings of thyroid gland from BRAF^(V600E) transgenic mice with a period of 60 weeks. Materials and Methods: We histologically inspected 3, 9, 20, 27, 39, 44, 48 and 60 week old BRAF^(V600E) transgenic mice derived from FVB/N background mice with a bovine thyroglobulin promoter which are providing thyroid specific BRAF^(V600E) expression. Results: Thyroid glands from 3 and 9 week old BRAF^(V600E)transgenic mice were enlarged and showed abnormal histologic feature such as distorted follicular architectures. The 20 and 27 week old BRAF^(V600E) transgenic mice showed irregularly enlarged thyroid gland sprouting out above the carotid arteries. Thyroid gland derived from 39 week old mice showed reduced formation of intact follicular structure and increased solid area. Thyroid glands were entirely replaced by firm tumor mass composed of poorly differentiated cell at 44 weeks. Interestingly, we could observe tracheal invasion, surrounding muscle invasion in thyroid gland from 48 week old mice and detect lung metastasis in 60 week old mice. Conclusion: Thyroid specific expression of BRAF^(V600E) induced staged development of thyroid cancer. This finding may support that BRAF^(V600E)have a role in entire carcinogenic process such as tumor initiation, development and progression.
Abstract
Background and Objectives: The BRAF^(V600E) mutation has been regarded as the leading cause of papillary thyroid cancer (PTC). However, the multi-step carcinogenic process induced by BRAF^(V600E) has been remained to be elucidated in thyroid gland. In this study, to investigate staged development of papillary thyroid carcinoma, we observed the histo-pathological findings of thyroid gland from BRAF^(V600E) transgenic mice with a period of 60 weeks. Materials and Methods: We histologically inspected 3, 9, 20, 27, 39, 44, 48 and 60 week old BRAF^(V600E) transgenic mice derived from FVB/N background mice with a bovine thyroglobulin promoter which are providing thyroid specific BRAF^(V600E) expression. Results: Thyroid glands from 3 and 9 week old BRAF^(V600E)transgenic mice were enlarged and showed abnormal histologic feature such as distorted follicular architectures. The 20 and 27 week old BRAF^(V600E) transgenic mice showed irregularly enlarged thyroid gland sprouting out above the carotid arteries. Thyroid gland derived from 39 week old mice showed reduced formation of intact follicular structure and increased solid area. Thyroid glands were entirely replaced by firm tumor mass composed of poorly differentiated cell at 44 weeks. Interestingly, we could observe tracheal invasion, surrounding muscle invasion in thyroid gland from 48 week old mice and detect lung metastasis in 60 week old mice. Conclusion: Thyroid specific expression of BRAF^(V600E) induced staged development of thyroid cancer. This finding may support that BRAF^(V600E)have a role in entire carcinogenic process such as tumor initiation, development and progression.
참고문헌 (21)
- Davies H, "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)
- Tang KT, "BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications", J Chin Med Assoc, 73(3), pp.113~128 (2010)
- Kimura ET, "High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET", PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma, 2003, pp.63, 1454~1457
- Frattini M, "Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer", Oncogene, 23, pp.7436~7440 (2004)
- Knauf JA, "Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation", Cancer Res, 65, pp.4238~4245 (2005)
- Mitsutake N, "BRAF mediates RET", PTC-induced mitogen-activated protein kinase activation in thyroid cells: Functional support for requirement of the RET, Endocrinology, pp.2006, 147[DOI]
- Wan PT, "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF", Cell, 116, pp.855~867 (2004)
- Dankort D, "A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors", Genes Dev, 21, pp.379~384 (2007)
- Dhomen N, "Oncogenic Braf induces melanocyte senescence and melanoma in mice", Cancer Cell, 15, pp.294~303 (2009)
- Motti ML, "Loss of p27 expression through RAS→BRAF→MAP kinase-dependent pathway in human thyroid carcinomas", Cell Cycle, 6, pp.2817~2825 (2007)
- Volante M, "Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid", Virchows Arch, 445, pp.183~188 (2004)
- Saggiorato E, "Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas", J Endocrinol Invest, 27, pp.311~317 (2004)
- Nikiforova MN, "BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas", J Clin Endocrinol Metab, 88, pp.5399~5404 (2003)
- Cantwell-Dorris ER, "BRAFV600E: Implications for carcinogenesis and molecular therapy", Mol Cancer Ther, 10, pp.385~394 (2011)
- Powell DJ Jr, "The RET", PTC3 oncogene: Metastatic solid-type papillary carcinomas in murine thyroids, 1998, pp.58, 5523~5528
- Nucera C, "BRAFV600E and microenvironment in thyroid cancer: A functional link to drive cancer progression", Cancer Res, 71, pp.2417~2422 (2011)
- Romei C, "BRAFV600E mutation, but not RET", PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer, 2008, pp.15, 511~520
- Mesa C Jr, "Conditional activation of RET", PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling, 2006, pp.66, 6521~6529
- Franco AT, "Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice", Proc Natl Acad Sci U S A, 108(4), pp.1615~1620 (2011)
- Wajapeyee N, "Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7", Cell, 132, pp.363~374 (2008)
- Decarlo K, "Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions?", Hum Pathol, 41, pp.886~894 (2010)